Tags

Type your tag names separated by a space and hit enter

Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin.
Clin Infect Dis. 2000 Aug; 31(2):493-8.CI

Abstract

The purpose of this prospective study was to update epidemiological data on cutaneous larva migrans (CLM) and to assess the therapeutic efficacy of ivermectin. We performed the study between June 1994 and December 1998 at our travel clinic. Ivermectin (a single dose of 200 microg/kg) was offered to all the patients with CLM, and its efficacy and tolerability were assessed by a questionnaire. Sixty-four patients were enrolled. All were European and had stayed in tropical areas. After the patients had returned from their destinations, 55% had lesions occur within a mean of 16 days (range, 1-120 days; >1 month in 7 patients). The initial diagnosis was wrong in 55% of patients. The mean number of lesions was 3 (range, 1-15), and the main sites were the feet (48%) and buttocks (23%). The cure rate after a single dose of ivermectin was 77%. In 14 patients, 1 or 2 supplementary doses were necessary, and the overall cure rate was 97%. The median time required for pruritus and lesions to disappear was 3 and 7 days, respectively. No systemic adverse effects were reported. Physicians' knowledge of CLM, which can have a long incubation period, is poor. Single-dose ivermectin therapy appears to be effective and well tolerated, even if several treatments are sometimes necessary.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Bouchaud O
Department of Infectious and Tropical Diseases, Hôpital Bichat Claude Bernard, Paris, France. olivier.bouchaud@bch.ap-hop-paris.fr
Houzé S
No affiliation info available
Schiemann R
No affiliation info available
Durand R
No affiliation info available
Ralaimazava P
No affiliation info available
Ruggeri C
No affiliation info available
Coulaud JP
No affiliation info available

MeSH

AdolescentAdultAgedAncylostomiasisAnimalsAntinematodal AgentsChildChild, PreschoolFemaleHumansInfantIvermectinLarva MigransMaleMiddle AgedProspective StudiesSurveys and QuestionnairesTravel

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10987711

Citation

Bouchaud, O, et al. "Cutaneous Larva Migrans in Travelers: a Prospective Study, With Assessment of Therapy With Ivermectin." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 31, no. 2, 2000, pp. 493-8.
Bouchaud O, Houzé S, Schiemann R, et al. Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. Clin Infect Dis. 2000;31(2):493-8.
Bouchaud, O., Houzé, S., Schiemann, R., Durand, R., Ralaimazava, P., Ruggeri, C., & Coulaud, J. P. (2000). Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 31(2), 493-8.
Bouchaud O, et al. Cutaneous Larva Migrans in Travelers: a Prospective Study, With Assessment of Therapy With Ivermectin. Clin Infect Dis. 2000;31(2):493-8. PubMed PMID: 10987711.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cutaneous larva migrans in travelers: a prospective study, with assessment of therapy with ivermectin. AU - Bouchaud,O, AU - Houzé,S, AU - Schiemann,R, AU - Durand,R, AU - Ralaimazava,P, AU - Ruggeri,C, AU - Coulaud,J P, Y1 - 2000/09/07/ PY - 2000/01/21/received PY - 2000/9/15/pubmed PY - 2001/2/28/medline PY - 2000/9/15/entrez SP - 493 EP - 8 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 31 IS - 2 N2 - The purpose of this prospective study was to update epidemiological data on cutaneous larva migrans (CLM) and to assess the therapeutic efficacy of ivermectin. We performed the study between June 1994 and December 1998 at our travel clinic. Ivermectin (a single dose of 200 microg/kg) was offered to all the patients with CLM, and its efficacy and tolerability were assessed by a questionnaire. Sixty-four patients were enrolled. All were European and had stayed in tropical areas. After the patients had returned from their destinations, 55% had lesions occur within a mean of 16 days (range, 1-120 days; >1 month in 7 patients). The initial diagnosis was wrong in 55% of patients. The mean number of lesions was 3 (range, 1-15), and the main sites were the feet (48%) and buttocks (23%). The cure rate after a single dose of ivermectin was 77%. In 14 patients, 1 or 2 supplementary doses were necessary, and the overall cure rate was 97%. The median time required for pruritus and lesions to disappear was 3 and 7 days, respectively. No systemic adverse effects were reported. Physicians' knowledge of CLM, which can have a long incubation period, is poor. Single-dose ivermectin therapy appears to be effective and well tolerated, even if several treatments are sometimes necessary. SN - 1058-4838 UR - https://www.unboundmedicine.com/medline/citation/10987711/Cutaneous_larva_migrans_in_travelers:_a_prospective_study_with_assessment_of_therapy_with_ivermectin_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/313942 DB - PRIME DP - Unbound Medicine ER -